* Nine more biotechs filed for HK IPOs (Adds Ascletis declined to comment on pricing): HONG KONG (Reuters/IFR) - Chinese biotech Ascletis Pharma Inc (1672.HK) raised $400 million after pricing its IPO in the middle of an indicative range, three people said, in the first such Hong Kong listing under rules designed to attract early-stage biotech firms. The initial public offering (IPO) is widely seen as a test of the new regime as Hong Kong seeks to establish itself as a financing center for the growing number of Chinese drug developers.